Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been given a consensus rating of “Hold” by the five ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $6.3333.

A number of brokerages have recently issued reports on OKYO. B. Riley Financial assumed coverage on OKYO Pharma in a research note on Monday, December 8th. They issued a “buy” rating and a $5.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of OKYO Pharma in a report on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Thursday, January 22nd. Finally, Piper Sandler initiated coverage on shares of OKYO Pharma in a research note on Friday. They issued an “overweight” rating and a $7.00 price objective for the company.

Hedge Funds Weigh In On OKYO Pharma

Several institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in shares of OKYO Pharma during the 3rd quarter worth about $31,000. XTX Topco Ltd acquired a new position in OKYO Pharma during the 4th quarter worth approximately $36,000. Finally, Renaissance Technologies LLC boosted its holdings in OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares in the last quarter. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Stock Down 3.4%

NASDAQ:OKYO opened at $1.70 on Friday. OKYO Pharma has a 52 week low of $1.03 and a 52 week high of $3.35. The firm’s fifty day moving average is $2.11 and its 200-day moving average is $2.21.

OKYO Pharma (NASDAQ:OKYO) last released its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($2.21). On average, research analysts forecast that OKYO Pharma will post -0.17 earnings per share for the current year.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.